Metastatic Urothelial Carcinoma COE

Metastatic Urothelial Carcinoma COE

Search

EV-302 Trial Establishes Treatment Standard for Urothelial Carcinoma - Daniel Petrylak Details David Crawford discusses advancements in advanced urothelial cancer treatment with Daniel Petrylak. Dr. Petrylak highlights the success of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, combined with pembrolizumab. This combination demonstrates significant improvements in response rates and survival compared to standard chemotherapy, with a 30% complete response rate and d...
The Final Results of KEYNOTE-361 - Ajjai Alva Details Immune checkpoint blockade therapy by blocking PD-1/PD-L1 axis signaling is approved in advanced urothelial cancers in a few settings: (1) first-line therapy for platinum-ineligible patients, (2) first-line therapy in cisplatin-ineligible patients with high PD-L1 expression, (3) maintenance therapy for patients who do not progress with first-line chemotherapy, and (4) as subsequent therapy for pat...
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo Details Ashish Kamat, MD, MBBS, welcomes Andrea Apolo, MD, the chief of the Bladder Cancer Section at the National Cancer Institute, to review new arrivals in the therapeutic options for the management of metastatic bladder cancer. Dr. Apolo summarizes which checkpoint inhibitors were approved by the U.S. Federal Drug Administration (FDA) for second-line treatment of metastatic urothelial carcinoma as wel...
Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas Details Alicia Morgans hosts Bishoy Faltas in a discussion about a Nature Communications publish article Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling which Bishoy was a co-author on with Brian D Robinson et al. In this study an integrated analysis of whole-exome and RNA sequencing of upper tract urothelial carcinoma (UTUC) was performed...
Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas Details In the rapidly evolving landscape of urothelial cancer, Alicia Morgans and Petros Grivas discuss biomarker testing in patients in urothelial cancer with an emphasis on muscle-invasive and metastatic disease. Having an effect on the day to day treatment algorithms, Petros fields questions in the metastatic setting including who are the patients we are testing and how we are using the results. Biogr...
Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg Details Jonathan Rosenberg, MD, discusses results presented of "Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Gemcitabine and Cisplatin with Bevacizumab or Placebo in Patients with Metastatic Urothelial Carcinoma — CALGB 90601" (Alliance). Dr. Rosenberg confirms that the addition of bevacizumab did not improve overall survival when added to gemcitabine and cisplatin chemotherapy a...